Merck & Co., Inc. (MRK)
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug
The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided missiles".
China grants licence to Merck's KEYTRUDA for stomach cancer treatment
China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.
Merck shares drop 10% as pharma giant scraps trial of promising cancer drug
Merck & Co's Frankfurt-listed shares fell 10% on Tuesday morning after the pharmaceutical giant said it had decided to call off a Phase III trial of its cancer drug Xevinapant, in an unexpected turn that threatens to undermine confidence in the company's research abilities.
Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know
Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session.
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
Merck (MRK) closed at $127.99 in the latest trading session, marking a +0.38% move from the prior day.
Merck Stock Edges Higher on FDA Vaccine Approval
The U.S. Food and Drug Administration (FDA) approved Merck & Co Inc's (NYSE:MRK) next-generation vaccine to protect adults against the pneumococcal disease.
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
US FDA approves Merck's pneumococcal vaccine for adults
Merck said on Monday the U.S. Food and Drug Administration has approved its next-generation vaccine to protect adults against pneumococcal disease.
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections
The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia. An advisory panel to the Centers for Disease Control and Prevention will meet on June 27 to discuss who should be eligible for the shot, called Capvaxive
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Merck (MRK) stood at $130.20, denoting a -1.24% change from the preceding trading day.
